Lexicon Pharmaceuticals (LXRX) Q3 2024 earnings summary

Executive summary

• Completed NDA resubmission for ZYNQUISTA in T1D and CKD; FDA AdCom voted 11-3 against benefit-risk in primary population, but robust support for 60-90 eGFR subgroup; PDUFA date set for December 20, 2024.

• Strategic repositioning executed, including a 50% reduction in field force and focused promotion of INPEFA to high prescribers.

• Advanced late-stage pipeline: phase III SONATA-HCM study for sotagliflozin in HCM enrolling, phase IIb PROGRESS study for LX9211 in DPNP completed enrollment ahead of schedule, and IND-enabling studies for LX9851 in obesity underway.

• Signed exclusive licensing agreement with Viatris for sotagliflozin outside US/EU, securing $25M upfront and up to $200M in milestones plus royalties.

• Net loss for Q3 2024 was $64.8M, with increased R&D and SG&A expenses as the company commercializes INPEFA and advances its pipeline.

Financial highlights

• Q3 2024 net sales of INPEFA reached $1.7M, up 8% sequentially; year-to-date sales at $4.5M.

• Total Q3 2024 revenues were $1.8M, nearly all from INPEFA.

• R&D expenses rose to $25.8M (from $17.6M in Q3 2023), driven by late-stage clinical investments.

• SG&A expenses increased to $39.6M (from $32.2M in Q3 2023), reflecting higher marketing and severance costs.

• Cash and investments totaled $258.4M as of September 30, 2024, up from $170.0M at year-end 2023.

Outlook and guidance

• Preparing for all ZYNQUISTA PDUFA outcomes; launch readiness plans paused pending FDA decision.

• If approved, ZYNQUISTA could launch as early as Q1 2025, targeting a concentrated endocrinologist market.

• Top-line data for LX9211 in DPNP expected in Q1 2025; IND filing for LX9851 anticipated mid-2025.

• Modest quarter-over-quarter growth expected for INPEFA, with continued payer engagement and focus on depth among prescribers.

• Current cash and investment balances, plus future revenues, are expected to fund planned operations for at least the next 12 months.